ArticleDaru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences2026
Unveiling the multitarget anticancer potential of Cochlospermum religiosum: phytochemical profiling, molecular docking, and in vitro/in vivo validation.
Article in Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCochlospermum religiosum (CR) is a traditionally valued medicinal plant, but its anticancer constituents and mechanisms remain poorly understood.
objectiveThis study aimed to investigate the anticancer potential of CR by integrating phytochemical profiling, molecular docking, and in vitro/in vivo evaluations.
methodsGC-MS and LC-MS analyses were performed to identify bioactive compounds in CR. Molecular docking was carried out against key cancer targets (CDK-2, CDK-6, IGF-1R, Bcl-2, and VEGFR-2). In vitro cytotoxicity was tested on MCF-7 (breast) and HT29 (colon) cancer cell lines, and in vivo efficacy was evaluated in an Ehrlich Ascites Carcinoma (EAC) mouse model. Haematological and hepatic parameters were also assessed.
resultsSeveral bioactive compounds were identified, including euphornin (reported for the first time in CR), lupeol, and stigmasterol, all with known anticancer activity. Docking studies suggested strong multitarget inhibitory potential. CR extract showed selective cytotoxicity against MCF-7 and HT29 cells with IC₅₀ values of ~ 33-42 µg/mL, while sparing normal cells. In the EAC mouse model, a 400 mg/kg dose of CR significantly reduced tumor burden, improved survival, and restored haematological (↑hemoglobin, ↑lymphocytes) and hepatic (↓SGOT, ↓SGPT, ↓bilirubin) parameters.
conclusionsCochlospermum religiosum exhibits promising multitarget anticancer potential, coupled with immunomodulatory and hepatoprotective effects. These findings provide a strong foundation for further mechanistic and clinical investigations.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.